Post-traumatic stress disorder (PTSD) is a severe psychiatric disorder that develops in a subset of people following a traumatic event. Exposure-based psychological treatments and antidepressants are the current first-line treatments for PTSD symptoms. However, many patients fail to receive effective treatments, drop out treatments, or are non-responsive to existing treatments (Watts et al, 2013) , highlighting an urgent unmet need to develop novel therapeutics. Part of the challenge in developing effective therapies has been the biological heterogeneity in PTSD pathophysiology. 'Broad-spectrum' therapies such as antidepressants and standardized exposure therapies may not account for the biological diversity of the underlying deficits in neurotransmitter mechanisms, stress resiliency, and learning deficits. One of the novel targets that has emerged as being involved in PTSD with strong preclinical and human data is the endocannabinoid system. The endocannabinoid system includes two principal cannabinoid receptors (CB1R and CB2R), their several endogenous ligands, including the two key ligands anandamide and 2-arachidonoylglycerol (2-AG), and enzymes responsible for endocannabinoid biosynthesis and inactivation. Although there are some conflicting findings, perhaps due to differences in experimental conditions, preclinical studies of fear disorder models generally support the concept that selective agonists of CB1R facilitate fear extinction. Subjects with PTSD are reported to have significantly lower CB1R availability and reduced peripheral concentration of anandamide (Pietrzak et al, 2014; Neumeister et al, 2015) and appears to be associated with threat processing in trauma survivors (Pietrzak et al, 2014) . These data suggest that low anandamide levels and upregulation of endocannabinoid receptors in the amygdale-hippocampal-corticostriatal circuitry could result in the enhanced reactivity to threat stimuli, and endogenous cannabinoid would ameliorate such responses (Neumeister et al, 2015) .
Despite this strong mechanistic rationale, utilizing direct agonists of CB1R receptors has several disadvantages. The CB1 receptors regulate many opposing functions in brain, especially in the regulation of fear regulation circuitry and downregulation of receptors are seen after chronic exposure to agonists. Agonists could also have adverse effects from offtarget CB1 activation. Therefore, alternative approaches to augment endocannabinoid signaling need to be explored. One such promising approach is through inhibition of fatty acid amide hydrolase (FAAH) involved in endocannabinoid catabolism that would increase the availability of endogenously generated endocannabinoids (Gunduz-Cinar et al, 2013) .
A second approach is to utilize positive allosteric modulators (PAMs) that selectively increase the CB1R effects. CB1R has allosteric sites spatially distinct from the orthosteric ligand-binding pocket, and engagement of CB1R by allosteric modulators induce a conformational change in the receptor that may be difficult to achieve with orthosteric ligands alone .................................................................................................................................................................. and thus one can 'fine-tune' the pharmacological activity of the endogenous ligand. Such compounds could offer not only enhanced CB1R selectivity, but also reduced receptor downregulation and inter-receptor promiscuity (Kulkarni et al, 2016) . One such compound GAT211 increases CB1R effects, demonstrates good efficacy in rodent models of chronic pain without demonstrating acute tolerance, rewarding properties or dependence (Slivicki et al, 2017) . Our preliminary data show that GAT211 also enhances fear extinction in auditory cue-induced fear conditioning model and could potentially provide a novel approach to PTSD drug development.
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The work was supported by National Institutes of Health grants MH52619 to AS and DA027113 and EY024717 to G. A.T. GAT is a co-inventor on the patents filed by Northeastern University for the CB1 PAMS. The remaining author declares no conflict of interest. Neuropsychopharmacology research is between a rock and a hard place. The rock is the historical, but slow, hypothesis-driven approach, where discovery occurs by testing candidate mechanisms in already well-known biological models. The hard place is the innovative, but overwhelming, hypothesis-free approach, where 'omics' analyses of everything that is analyzable generates a deluge of data implicating hitherto unknown mechanisms. So, either we have little data on things we already know, or too much data and cannot find the needle in a haystack. One solution is to mix apples and oranges: integrating cross-species and crosstissues 'omics' data to find mechanisms that recur across different experimental and clinical models. The idea has been used with remarkable success. And yes, we will finish with the proverbs now.
Niculescu et al (2000) first developed and used such an approach, which they called convergent functional genomics. More recently, the approach has been used by them to help prioritize genes from genome-wide association studies (GWAS) of bipolar disorder (Patel et al, 2010) , integrating GWAS findings, transcriptomics data on postmortem human brain and blood, and studies in animal models, to identify top-genes supported by all approaches. They identified six genes (ARNTL, MBP, BDNF, NRG1, RORB, and DISC1), which are involved in relevant biological processes, such as circadian rhythm, connectivity, and neuroplasticity. They used a similar strategy for schizophrenia (Ayalew et al, 2012) . Interestingly, this strategy could be done with publically available data rather than being based on novel experimental findings.
In 2013, we studied transcriptomics data from the hippocampus of adult prenatally stressed rats (an established animal model of depression with high glucocorticoid levels) and from a human neuronal stem cell line (that we treated with a concentration of cortisol that reduces neurogenesis) (Anacker et al, 2013) . We found that TGFβ-SMAD2/3 and Hedgehog signaling are reduced in both models: TGFβ-SMAD2/3 promotes neurogenesis (and has been found to be reduced in depressed patients), whereas Hedgehog promotes neuronal differentiation (and has not been studied in depressed patients yet). Similarly, Malki et al (2016) studied transcriptomics from the prefrontal cortex of mice bred for high aggressive behavior and from the brain of zebrafish exposed to aggressive social encounters. They identified seven genes shared in both datasets, including HDAC4, which has genetic variants associated with aggressive behavior in mental retardation, and it is targeted by valproic acid, a pharmacological treatment for aggressive behavior. Finally, Luoni et al (2016) studied methylome analyses performed in multiple models of early life stress: rats exposed to prenatal stress (prefrontal cortex); human newborns exposed to stress in pregnancy (cells from the umbilical cord); and rhesus monkeys exposed to stressful rearing conditions (peripheral blood and prefrontal cortex). Their top gene was Ank3, a gene with a strong association for psychiatric disorders; and they also demonstrated an interaction between functional genetic variants within Ank3 gene and obstetric complications on working memory in humans. Although these studies are predominantly 'comparative' in their nature, this cross-species and cross-tissues approach can be used to produce 'integrative' findings when it generates
